Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1247, 2000-01, pp. : 7-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IFN- cost effective for MS after all?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. :
Access to resources
Recommend
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. :
Cancer treatment in clinical trials not so costly after all?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 279, 2000-01 ,pp. :
Is there still a place for high-dose methotrexate in paediatric ALL?
Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. :
Omalizumab for severe allergic asthma: cost effective all round?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. :